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How to assess moderate effects of medicaltreatment? Suppose that a preventive type ofreatment for cardiovascular death would be able
to reduce 20% of such an outcome. Let us assume that the
expected incidence of death due to cardiovascular disease
is 10% per year.
If 1,000 cases were properly randomized and 100%
of them were followed up, the expected deaths in the
control group would be 50 (10% of 500) and the incidence
in the treated group would be around 40 deaths (20% risk
reduction). In this situation, results may be attributed to
chance (P > 0.05). In order to detect an actual difference,
or in other words, to have the statistical power to detect
such a difference, it would be necessary to study thousands
of patients. Conducting a clinical trial like this requires
collaborative multicenter research, trained personnel and
extensive funding. However such a task is possible, and
we do have good examples like the ISIS-2 studies - The
Second International Study of Infarct Survival. The ISIS-
2 study has included 17,187 cases of suspected acute
myocardial infarction showing odds reduction of 25% in
mortality by using low doses of aspirin.
There is still another method of assessing the
moderate effects of treatment assuming that some clinical
trials have already been carried out, published or not, that
can be studied through a systematic review. With this
method, all the randomized clinical trials performed on a
subject will be searched out worldwide, and the results
will be put together (after excluding the ones not
considered properly designed or conducted).
I would refer the interested reader to three
publications of the Antiplatelets Trialists' Collaboration
(1) - the "Aspirin Papers" in the British Medical Journal.
The first publication is a masterpiece of systematic
review and has a very clear explanation of the methodology
and the statistical treatment applied to the development of
these systematic reviews. Again it was a collaborative
enterprise (ATC) and the results show an important
reduction of cardiovascular events, cardiovascular death
and deaths in general when antiplatelet therapy is
preventively administered to high-r'isk patients. The
authors considered high-risk the patients with a history of
myocardial infarction, stroke or transient ischemic attack,
or a mixed category of increased risks of vascular events
that included diabetes and renal diseases. The benefit of
this treatment was not observed in the low-risk group.
Through this review, which took many years of effort
and required more goodwill than funding, an important
question was eventually answered and medical practice
improved.
Simple and large clinical trials - provided that they
are well designed and conducted - and systematic
reviews, are two types of collaborati ve studies that are
appropriate to assess the moderate effects of treatment
which may have a high clinical significance.
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